The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

@inproceedings{Frederich2012TheEA,
  title={The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-na{\"i}ve patients with type 2 diabetes mellitus: a randomized controlled trial},
  author={Robert C. Frederich and Robert McNeill and Niklas Berglind and Douglas Theodore Fleming and Roland Chen},
  booktitle={Diabetology & metabolic syndrome},
  year={2012}
}
UNLABELLED BACKGROUND The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks. METHODS 365 treatment-naïve patients with T2DM (HbA1c 7.0%-10.0%) were treated with saxagliptin 2.5 mg q.A.M., saxagliptin 2.5 mg q.A.M. with possible titration to saxagliptin 5 mg, saxagliptin 5 mg q.A.M., saxagliptin 5 mg q.P.M., or placebo… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Similar Papers

Loading similar papers…